Lupin share price

Lupin stock gains after pharma major carves out consumer healthcare unit

Jul 01, 2025, 09:28 PM IST

The move is part of Lupin's broader strategy to create a specialised consumer healthcare entity, particularly aimed at capitalising on India's burgeoning self-care market.

Lupin shares: Brokerage sees 23% upside potential, anticipates high growth with new US launches

May 16, 2025, 04:14 PM IST

Lupin has guided for a quarterly base revenue of $250 million from its US operations, bolstered by the upcoming launches of generic versions of gJynarque and gXarelto.

Aurobindo, Sun Pharma, other pharma stocks in focus after 90-day Trump tariff pause

Apr 10, 2025, 03:32 PM IST

Aurobindo Pharma and Gland Pharma have fallen 9 per cent each in the past one week and 22-23 per cent in 2025 so far. Glenmark Pharma is down 9 per cent for the week month period and 14 per cent year-to-date.

Pharma stocks crack up to 10% as Trump warns of 'never seen before' tariffs

Apr 04, 2025, 05:31 PM IST

Granules India, Lupin, Gland Pharma and Cipla fell 5-6 per cent. Sun Pharmaceutical Industries slipped 5 per cent while Dr Reddy's Labs was down 4 per cent.

Trump tariff: Aurobindo Pharma, Gland, Lupin, DRL shares rally up to 7%; here's why

Apr 03, 2025, 03:16 PM IST

Gland Pharma surged 7.33 per cent to Rs 1,647.65. Aurobindo Pharma, the largest Indian generic company with US sales, soared 6.53 per cent to Rs 1,234.35. Lupin climbed 6.35 per cent Rs 2,137.

Earnings Impact! Lupin Shares Rebound After Strong Q3, MGMT Shares Positive Outlook

Feb 13, 2025, 05:27 PM IST

Lupin Q3 FY25 Results: Strong Growth in Profitability | Exclusive with CFO Ramesh Swaminathan. Lupin has reported a robust Q3 FY25 performance, showcasing double-digit sales growth and significant margin expansion. Despite market volatility, the company has delivered strong profitability and operational efficiency. Key Highlights: 📈 Sales: ₹56,186 Mn | Up 10.6% YoY | Up 2.2% QoQ 💰 EBITDA: ₹14,096 Mn | Up 32.1% YoY | Up 1.9% QoQ 📊 EBITDA Margin: 25.1% | +408 bps YoY | -7 bps QoQ 📌 PBT: ₹10,713 Mn | Up 45.5% YoY | Up 1.6% QoQ 🏦 PAT: ₹8,589 Mn | Up 38.8% YoY | Flat QoQ Financial Insights: 🔹 Gross Profit: ₹38,970 Mn | 69.4% Margin 🔹 Employee Benefits: ₹9,844 Mn | 17.5% of Sales 🔹 Manufacturing & Other Expenses: ₹16,959 Mn | 30.2% of Sales 🔹 R&D Investment: ₹4,344 Mn | 7.7% of Sales 📺 Exclusive Interview: Join us on Business Today TV as Ramesh Swaminathan, Executive Director, Global CFO & Head of API Plus at Lupin, shares insights on the company's Q3 performance, strategic priorities, and growth outlook for the coming quarters.

Lupin, Vodafone, IRCTC, Berger Paints, SAIL & NBCC: How these stocks are faring ahead of Q3 results

Feb 11, 2025, 04:42 PM IST

Select renowned companies including Lupin, Vodafone Idea, NBCC (India), SAIL, Berger Paints and IRCTC are set to announce their results for December 2024 quarter later today.

Reliance Industries, Eicher Motors, Lupin: 3 stock picks for short-term gains

Jan 08, 2025, 01:36 PM IST

An analyst from Master Capital Trust said that Reliance is witnessing a strong bullish setup on the monthly chart as prices find support near the rising trendline, which has been intact for an extended period.

Cipla, Glenmark Pharma, Lupin: How to trade these 3 buzzing pharma stocks

Nov 14, 2024, 12:53 PM IST

An analyst from YES Securities said that Lupin has broken down from a descending triangle pattern on daily timeframe, signaling a negative trend and sellers appear increasingly aggressive.

Dr Reddy's Labs, Lupin, Divi's Labs: How to trade these buzzing pharma stocks

Oct 10, 2024, 12:45 PM IST

An analyst at YES Securities said that Dr Reddy's Labs has undergone a significant correction from the peak and has approached the 100-day SMA and 38.2 per cent Fibonacci retracement.

Buy Tech Mahindra, Lupin & Chalet Hotels shares, says LKP Securities

Aug 27, 2024, 01:18 PM IST

An analyst from LKP Securities said that Tech Mahindra has given a downward consolidation breakout on the daily chart, indicating increased optimism, supported by higher volume.